your market intelligence analyst
Search Results
27 results
Your search is now limited to «Eli Lilly» expert search.
ENDPOINTS 04/03/2020 10:43
Can a Chinese biotech deliver the first new lupus drug in decades? A high-profile group of VCs are betting on it. Lilly Asia Ventures and Lake Bleu Capital are the co-headliners for RemeGen’s , which brought in more than $100 million. Hudson Bay Capital and Vivo Capital — which, like LAV, also invested in a pre-IPO round for Legend Biotech unveiled today — chimed in, as did Janchor Partners and OrbiMed. Jianmin Fang. RemeGen got going in 2008 when Jianmin Fang, a Canada-educated scientist who trained at Harvard Medical School, convinced his friends at a traditional Chinese medicine company to launch a biologics player with him, the founder told Endpoints News . He’s served as the CEO and CSO since then. Initially focused on antibodies and fu.

Personal Care

Household Products

Business Issues


Companies - Public

Companies - Venture Funded

Information Technologies


Job Titles